MEREO BIOPHARMA GROUP PL-ADR (MREO)
US5894921072 - ADR
ChartMill assigns a Buy % Consensus number of 86% to MREO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.38. This target is 94.95% above the current price.
MREO was analyzed by 10 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about MREO.
In the previous month the buy percentage consensus was at a similar level.
MREO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-28 | Needham | Maintains | Buy -> Buy |
| 2024-03-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-08 | Needham | Reiterate | Buy -> Buy |
| 2023-08-23 | Needham | Reiterate | Buy -> Buy |
| 2023-06-06 | Needham | Reiterate | Buy -> Buy |
| 2023-05-26 | Needham | Reiterate | Buy -> Buy |
| 2023-04-21 | Needham | Reiterate | Buy |
| 2023-03-30 | Needham | Reiterate | Buy |
| 2022-11-10 | SVB Leerink | Maintains | Outperform |
| 2022-08-12 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-06-06 | Needham | Maintains | Buy |
| 2021-05-05 | BTIG | Initiate | Buy |
| 2021-04-05 | Needham | Initiate | Buy |